Today's Date: May 19, 2024
Upneeq® Wins 2024 Shape Skin Award, “Best for Lift”, in the Professional Treatment Category   •   Energy Vault Holdings, Inc. Announces Inducement Grants Under NYSE Listing Rule 303A.08   •   Red Door Community Raises more than $300,000 at Their Annual Luncheon Celebrating Women Working and Living with Cancer   •   Federal, provincial and territorial ministers gather to support culture and heritage at annual meeting   •   Rockwell Institute Celebrates Highest Real Estate Exam Pass Rates for First-Time Test Takers in the State of Washington   •   Angels Helpers NYC 2024 Charity Gala Raises Funds for Harlem School of the Arts, Highbridge Voices   •   Xylem Inc. Declares Second Quarter Dividend of 36 Cents per Share   •   L.A. Care and Blue Shield of California Promise Health Plans Unveil New, Vibrant Community Resource Center in Panorama City with   •   Aramco and Spiritus to Advance Direct Air Capture Technology, Investment by Aramco Ventures   •   The AZEK Company Receives NYSE Notice Regarding Filing of Form 10-Q for the Fiscal Quarter Ended March 31, 2024   •   Historic Inaugural Class Graduates from OSU College of Osteopathic Medicine at the Cherokee Nation   •   Dillard’s, Inc. Announces $0.25 Cash Dividend   •   Historic Bellevue House reopens   •   HERImpact: Entrepreneurship for Impact Program Kicks Off in Chicago, Empowering Women Entrepreneurs   •   Avangrid to Be Acquired by Iberdrola   •   Statement by the Prime Minister on Tamil Genocide Remembrance Day   •   After Launching Massive Camp Giveaway for NYC Families Affected by "Summer Rising" Crisis, Brains & Motion Education (BAM!)   •   WOMEN'S HEALTHCARE COMPANY WATKINS-CONTI RECEIVES FDA 510(K) CLEARANCE FOR NEW STRESS URINARY INCONTINENCE DEVICE YŌNI.FIT&   •   May and Stanley Smith Charitable Trust Partners with American Indian College Fund to Support Native Student Veterans   •   Sacred Heart Celebrates 125th Anniversary
Bookmark and Share

Exeltis USA, Inc. Sparks National Conversation About Health Equity, Inclusion and Body Positivity During Women’s Health Mo

FLORHAM PARK, N.J. , May 08 /Businesswire/ - Exeltis USA, Inc., a division of the global pharmaceutical group Insud Pharma, today announced “Let’s Love Every Body,” a national campaign designed to empower women to live life to the fullest while loving and accepting their bodies. The campaign features real stories from women of diverse body types, ages and cultural backgrounds discussing the need for every body (and everybody) to be loved, respected and welcomed in more spaces, especially in conversations about sexual health and birth control options. The campaign, refreshed for Women’s Health Month, also highlights Slynd (pronounced “slind”), a unique, estrogen-free birth control pill for women who can become pregnant to prevent pregnancy.*1

“We understand and celebrate the fact that women and their health needs can’t be met with a ‘one-size-fits-all’ approach, and we want to ensure that every woman has the support, knowledge and options needed to make the best choices to meet their unique needs, including contraceptive options,” said Rob Spina, CEO, Exeltis USA. “The ‘Let’s Love Every Body’ campaign is designed to build an inclusive community of women and get them talking about the importance of equity in healthcare and body positivity as they forge and follow their own paths to living healthy lives.”

Research shows that women are more affected by body dissatisfaction, a negative self-assessment of one’s own appearance – than men.2 The Slynd mission and Let’s Love Every Body initiative encourages women to be kind to and accepting of themselves and understand their contraceptive options that are right for them. “As a society, we must do more to lift women up and reinforce the fact that healthy bodies come in all different shapes and sizes at all different ages,” said Randi Rievman, VP Marketing & Strategic Communications, Exeltis USA. “As women take greater ownership of their health, they need to feel empowered to start an honest dialogue with their doctors to determine which method of birth control is right for them.”

Using authentic storytelling and the hashtag #LetsLoveEveryBody, the campaign includes a website with a personalized content journey, digital advertising, social media and brochures in doctor’s offices to reach and ready women nationwide to prioritize their health. For more information about the campaign and Slynd, please visit https://slynd.com/.

About Slynd

Slynd is an estrogen-free oral contraceptive pill.1 To learn more, join the Slynd community on Instagram, YouTube, TikTok, and Facebook. Help spread the message of body positivity, health equity, and healthy living to women across the country.

About Exeltis

Exeltis is a fast-growing division of Insud Pharma, an integrated health sciences group. It has developed a leading position in the women's health sector, where it continues to discover, develop, produce and seek new medicines and medical devices to improve the health and wellbeing of women around the world. With a geographical footprint spanning over 40 countries, Exeltis employs over 4,000 professionals supported by a global production network. Exeltis strives to provide care for women throughout their lives. Exeltis offers a broad portfolio of products to respond to patients' needs in the fields of fertility, reproductive health, contraception, pregnancy, birth, and menopause and has expanded its reach in recent years to central nervous system, ophthalmology and endocrinology. To learn more, please visit us on http://www.exeltisusa.com/ and follow us on Twitter or Facebook.

SLYND® Important Risk Information

Slynd does not protect against HIV infection (AIDS) and other sexually transmitted diseases (STDs).

What is SLYND?

SLYND is a birth control pill (oral contraceptive) that is used by females who can become pregnant to prevent pregnancy.

The progestin drospirenone may increase potassium levels in your blood. You should not take SLYND if you have kidney, liver or adrenal disease because this could cause serious heart problems as well as other health problems. Other medicines may also increase potassium levels in your blood. If you are currently on daily, long-term treatment for a chronic health condition with any of the medicines listed below, talk to your healthcare provider about whether SLYND is right for you. If you take any of the medicines listed below for a chronic health condition you should have a blood test to check the potassium level in your blood before you start taking SLYND and during the first month that you take SLYND.

  • medicines to treat fungal infections, such as ketoconazole, itraconazole, or voriconazole
  • medicines to treat Human Immunodeficiency Virus (HIV) infection or Hepatitis C infection, such as indinavir or boceprevir
  • clarithromycin

Do not take SLYND if you:

  • have kidney disease or kidney failure.
  • have reduced adrenal gland function.
  • have or have had cervical cancer or any cancer that is sensitive to female hormones.
  • have liver disease, including liver tumors.
  • have unexplained vaginal bleeding.

Tell your healthcare providers if you have or have had any of these conditions. Your healthcare provider can suggest a different method of birth control.

If any of these conditions happen while you are taking SLYND, stop taking SLYND right away and talk to your healthcare provider. Use non-hormonal contraception when you stop taking SLYND.

Before you take SLYND, tell your healthcare provider about all of your medical conditions, including if you:

  • are pregnant or think you may be pregnant.
  • have ever had blood clots in your legs (deep vein thrombosis), lungs (pulmonary embolism), or a stroke or heart attack (myocardial infarction).
  • have or have had depression.

Tell your healthcare providers about all the medicines you take including prescription and over-the- counter medicines, vitamins and herbal supplements, such as St. John’s Wort.

SLYND may affect the way other medicines work, and other medicines may affect how well SLYND works.

What are the possible serious side effects of SLYND?

SLYND may cause serious side effects, including:

  • High potassium levels in your blood (hyperkalemia). Certain medicines and conditions can also increase the potassium levels in your blood. Your healthcare provider may check the potassium levels in your blood before and during treatment with SLYND. Call your healthcare provider or go to a hospital emergency room right away if you have signs or symptoms of high potassium levels in your blood including:
    • weakness or numbness in an arm or leg.
    • palpitations (feel like your heart is racing or fluttering) or irregular heartbeat.
    • nausea.
    • vomiting.
    • severe pain in your chest.
    • shortness of breath.
  • Blood clot forming in blood vessels. Tell your healthcare provider if you have had a blood clot. Tell your healthcare provider if you plan to have surgery or are not able to be active due to illness or injury. Call your healthcare provider or go to a hospital or emergency room right away if you have:
    • leg pain that will not go away.
    • a sudden, severe headache unlike your usual headaches.
    • sudden, severe shortness of breath.
    • sudden change in vision or blindness.
    • chest pain.
    • weakness or numbness in your arm or leg.
    • trouble speaking.
  • Bone loss.
  • Cervical Cancer.
  • Liver problems, including liver tumors.
  • Ectopic pregnancy (pregnancy in your tubes). This is a medical emergency that often requires surgery. If you have severe abdominal pain, call your healthcare provider or go to a hospital emergency room right away.
  • Risk of high blood sugar levels in people with diabetes.
  • Changes in menstrual bleeding. Tell your doctor if you have changes in menstrual bleeding.
  • Depression, especially if you have had depression in the past.

What are the most common side effects of SLYND?

  • acne
  • headache
  • breast pain and tenderness
  • weight gain
  • menstrual cramps
  • nausea
  • severe vaginal bleeding
  • less sexual desire

These are not all the possible side effects of SLYND.

This is not all of the important information about SLYND. Please click here for Full Prescribing Information.

__________________________

Reference 1: Slynd package insert.

Reference 2: Eck, Kaitlyn et al., “Body Dissatisfaction, Eating Styles, Weight-Related Behaviors, and Health among Young Women in the United States,” Nutrients, 2022 Sep 19; 14(18): 3876

SLY-24-365 R00


STORY TAGS: Product/Service, General Health, Family, Specialty, Consumer, Pharmaceutical, Retail, Vacation, Teens, Mental Health, Parenting, Travel, Baby/Maternity, Marketing, Advertising, Fitness & Nutrition, Communications, Collegiate, Social Media, Bridal, Health, Search Engine Marketing, United States, North America, New Jersey,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News